文献速递血栓与止血

揭示免疫性血小板减少症成人患者肺栓塞风险与结局

Unmasking the link: pulmonary embolism risk and outcomes in adults with immune thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2026-05-09

基于7281例成人原发免疫性血小板减少症(ITP)患者的回顾性巢式病例对照研究,识别25例肺栓塞(PE),发生率0.46/1000人年。PE诊断中位年龄65岁,从ITP诊断至PE中位199天,76%患者已达ITP治疗反应。早期抗凝治疗结局良好,2例在PE诊断后30天内死亡。

要点

  • ITP成人患者PE发生率为0.46/1000人年,诊断PE时多数已获ITP治疗反应。
  • 血栓史和活动性恶性肿瘤是ITP后PE的独立危险因素。
  • 早期抗凝治疗可改善结局,但PE诊断后30天内仍有2例死亡。

核心结论

  • ITP成人患者存在肺栓塞风险,血栓史和活动性恶性肿瘤是独立危险因素,早期抗凝治疗可能改善结局。

研究设计与样本

  • 回顾性巢式病例对照研究,基于2011至2025年7281例成人原发ITP队列,按性别、年龄、ITP诊断时间和随访时长1:3匹配无PE的ITP患者。

主要发现

  • 共识别25例PE,发生率为0.46/1000人年;PE诊断中位年龄65岁,从ITP诊断至PE中位199天。
  • PE诊断时76%患者已获ITP治疗反应;早期抗凝治疗结局良好,2例在PE诊断后30天内死亡。

临床怎么用

  • 对ITP成人患者应关注肺栓塞风险,尤其有血栓史或活动性恶性肿瘤者。
  • PE诊断后早期启动抗凝治疗可能改善结局。

局限性

  • 回顾性巢式病例对照设计,PE事件数较少(25例),结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune thrombocytopenia (ITP) is known to increase bleeding risk, yet thrombotic complications, including pulmonary embolism (PE), remain overlooked, with limited clinical evidence. OBJECTIVES: This study aimed to characterize PE in patients with ITP and offer insights for clinical management. METHODS: We conducted a retrospective nested case-control study based on a cohort of 7281 adult patients with primary ITP between 2011 and 2025. For each patient with ITP and PE, 3 patients with PE-free ITP were randomly matched by sex, age, time of ITP diagnosis, and follow-up duration. Clinical characteristics, treatment modalities, and outcomes were analyzed and compared. Cox regression analyses were performed to identify potential risk factors. RESULTS: Twenty-five patients with PE were identified, with an incidence of 0.46 per 1000 person-years. The median age at PE diagnosis was 65 years, with a median of 199 days from ITP diagnosis to PE onset. At the time of PE diagnosis, 76% of the patients had achieved an ITP treatment response. Early anticoagulant therapy resulted in favourable outcomes, whereas 2 patients died within 30 days of PE diagnosis. Cox regression analysis revealed that a history of thrombosis (hazard ratio, 6.123; P = .002) and concurrent active malignancy (hazard ratio, 4.468; P = .045) were independent risk factors for PE following ITP diagnosis. Additional analyses identified factors associated with bleeding or thrombosis recurrence. CONCLUSION: This study provided insights into PE in adults with ITP, highlighted the risk factors, and summarized the experience regarding clinical management, which may help optimize outcomes for affected patients. CLINICAL TRIAL REGISTRATION: NCT07068425.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Zhang L, An Z, Zhao P, et al. Unmasking the link: pulmonary embolism risk and outcomes in adults with immune thrombocytopenia. J Thromb Haemost. 2026. PMID: 42114623. doi:10.1016/j.jtha.2026.04.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。